BPR2-D2 targeting viral ribonucleoprotein complex-associated function inhibits oseltamivir-resistant influenza viruses

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 1, 2009, Pages 63-71

  Shih, Shin Ru ^a,b,c,d   Horng, Jim Tong ^b,c   Poon, Leo L M ^e   Chen, Tzu Chun ^b   Yeh, Jiann Yih ^a   Hsieh, Hsing Pang ^a   Tseng, Sung Nain ^a   Chiang, Chiayn ^b   Li, Wan Ling ^c   Chao, Yu Sheng ^a   Hsu, John T A ^a,f  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b Research Center for Emerging Viral Infections   (Taiwan)

^c CHANG GUNG UNIVERSITY   (Taiwan)

^d CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^e UNIVERSITY OF HONG KONG   (Hong Kong)

^f NATIONAL CHIAO TUNG UNIVERSITY   (Taiwan)

Author keywords

Antiviral agent; Influenza A virus; Viral RNA

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; 8 BENZOYL 4 METHYL 9 PHENYLFURO[2,3 H]CHROMEN 2 ONE; AMANTADINE; ANTIVIRUS AGENT; BPR 2D 2; RIBONUCLEOPROTEIN; UNCLASSIFIED DRUG; VIRUS RNA; VIRUS SIALIDASE; ZANAMIVIR;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG STRUCTURE; DRUG TARGETING; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; INFLUENZA VIRUS A; INFLUENZA VIRUS B; NONHUMAN; RNA SYNTHESIS; VIRUS INHIBITION; VIRUS NEUTRALIZATION;

EID: 77950356637     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp393     Document Type: Article

References (45)

1. Suzuki Y. Sialobiology of influenza: molecular mechanism of host range variation of influenza viruses. Biol Pharm Bull 2005; 28: 399-408.
2. Palese P, Shaw ML. Orthomyxoviridae: the viruses and their replication. In: Knipe DM, Howley PM, Griffin DE et al., eds. Field's Virology. Philadelphia, PA: Lippincott Williams & Wilkins, 2007; 1647.
3. Johnson NP, Mueller J. Updating the accounts: global mortality of the 1918-1920 "Spanish" influenza pandemic. Bull Hist Med 2002; 76: 105-15.
4. Belshe RB. The origins of pandemic influenza-lessons from the 1918 virus. N Engl J Med 2005; 353: 2209-11.
5. Kilbourne ED. Influenza pandemics of the 20th century. Emerg Infect Dis 2006; 12: 9-14.
6. Buchy P, Mardy S, Vong S et al. Influenza A/H5N1 virus infection in humans in Cambodia. J Clin Virol 2007; 39: 164-8.
7. Chang SC, Cheng YY, Shih SR. Avian influenza virus: the threat of a pandemic. Chang Gung Med J 2006; 29: 130-4.
8. Gambotto A, Barratt-Boyes SM, de Jong MD et al. Human infection with highly pathogenic H5N1 influenza virus. Lancet 2008; 371: 1464-75.
9. Maines TR, Lu XH, Erb SM et al. Avian influenza (H5N1) viruses isolated from humans in Asia in 2004 exhibit increased virulence in mammals. J Virol 2005; 79: 11788-800.
10. Yuen KY, Wong SS. Human infection by avian influenza A H5N1. Hong Kong Med J 2005; 11: 189-99.
11. Jordan HT, Mosquera MC, Nair H. Swine-origin influenza A (H1N1) virus infections in a school-New York City, April 2009. MMWR Morb Mortal Wkly Rep 2009; 58: 470-2.
12. Ministry of Health, Mexico; Pan American Health Organization; World Health Organization; Public Health Agency of Canada; CDC. Outbreak of swine-origin influenza A (H1N1) virus infection-Mexico, March-April 2009. MMWR Morb Mortal Wkly Rep 2009; 58: 467-70.
13. Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 2009; 360: 2605-15.
14. Strategic Science and Program Unit, Coordinating Center for Infectious Diseases; Division of Global Migration and Quarantine, National Center for Preparedness, Detection, and Control of Infectious Diseases; Influenza Div, National Center for Immunization and Respiratory Diseases, CDC Influenza Emergency Response Team, CDC. Update: infections with a swine-origin influenza A (H1N1) virus-United States and other countries, April 28, 2009. MMWR Morb Mortal Wkly Rep 2009; 58: 431-3.
15. de Jong MD, Tran TT, Truong HK et al. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med 2005; 353: 2667-72.
16. Hayden FG, Pavia AT. Antiviral management of seasonal and pandemic influenza. J Infect Dis 2006; 194 Suppl 2: S119-26.
17. Le QM, Kiso M, Someya K et al. Avian flu: isolation of drug-resistant H5N1 virus. Nature 2005; 437: 1108.
18. Moscona A. Global transmission of oseltamivir-resistant influenza. N Engl J Med 2009; 360: 953-6.
19. Saito R, Li D, Suzuki H. Amantadine-resistant influenza A (H3N2) virus in Japan, 2005-2006. N Engl J Med 2007; 356: 312-3.
20. He G, Qiao J, Dong C et al. Amantadine-resistance among H5N1 avian influenza viruses isolated in Northern China. Antiviral Res 2008; 77:72-6.
21. Schmidtke M, Bauer K, Ludwig N et al. Emergence and phylogenetic relationships of amantadine-resistant human H3N2 influenza A viruses in Germany in the season 2005/2006. Int J Antimicrob Agents 2008; 32: 192-5.
22. Lee J, Song YJ, Park JH et al. Emergence of amantadine-resistant H3N2 avian influenza A virus in South Korea. J Clin Microbiol 2008; 46: 3788-90.
23. Bright RA, Medina MJ, Xu X et al. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet 2005; 366: 1175-81.
24. Bright RA, Shay DK, Shu B et al. Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA 2006; 295: 891-4.
25. Hauge SH, Dudman S, Borgen K et al. Oseltamivir-resistant influenza viruses A (H1N1), Norway, 2007-08. Emerg Infect Dis 2009; 15: 155-62.
26. Meijer A, Lackenby A, Hungnes O et al. Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007-08 season. Emerg Infect Dis 2009; 15: 552-60.
27. Hsieh HP, Hsu JT. Strategies of development of antiviral agents directed against influenza virus replication. Curr Pharm Des 2007; 13: 3531-42.
28. Malakhov MP, Aschenbrenner LM, Smee DF et al. Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection. Antimicrob Agents Chemother 2006; 50: 1470-9.
29. Furuta Y, Takahashi K, Kuno-Maekawa M et al. Mechanism of action of T-705 against influenza virus. Antimicrob Agents Chemother 2005; 49: 981-6.
30. Sidwell RW, Barnard DL, Day CW et al. Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice. Antimicrob Agents Chemother 2007; 51: 845-51.
31. Pleschka S, Jaskunas R, Engelhardt OG et al. A plasmid-based reverse genetics system for influenza A virus. J Virol 1996; 70: 4188-92.
32. Bienz K, Egger D, Pfister Tet al. Structural and functional characterization of the poliovirus replication complex. J Virol 1992; 66:2740-7.
33. Bienz K, Egger D, Pfister T. Characteristics of the poliovirus replication complex. Arch Virol Suppl 1994; 9: 147-57.
34. Schlegel A, Giddings TH Jr, Ladinsky MS et al. Cellular origin and ultrastructure of membranes induced during poliovirus infection. J Virol 1996; 70: 6576-88.
35. Suhy DA, Giddings TH Jr, Kirkegaard K. Remodeling the endoplasmic reticulum by poliovirus infection and by individual viral proteins: an autophagy-like origin for virus-induced vesicles. J Virol 2000; 74: 8953-65.
36. Herold J, Andino R. Poliovirus RNA replication requires genome circularization through a protein-protein bridge. Mol Cell 2001; 7: 581-91.
37. Van Dyke TA, Flanegan JB. Identification of poliovirus polypeptide P63 as a soluble RNA-dependent RNA polymerase. JVirol1980; 35: 732-40.
38. Poch O, Sauvaget I, Delarue M et al. Identification of four conserved motifs among the RNA-dependent polymerase encoding elements. EMBO J 1989; 8: 3867-74.
39. He X, Zhou J, Bartlam M et al. Crystal structure of the polymerase PA(C)-PB1(N) complex from an avian influenza H5N1 virus. Nature 2008; 454: 1123-6.
40. Sugiyama K, Obayashi E, Kawaguchi A et al. Structural insight into the essential PB1-PB2 subunit contact of the influenza virus RNA polymerase. EMBO J 2009; 28: 1803-11.
41. O'Reilly EK, Kao CC. Analysis of RNA-dependent RNA polymerase structure and function as guided by known polymerase structures and computer predictions of secondary structure. Virology 1998; 252: 287-303.
42. Momose F, Naito T, Yano K et al. Identification of Hsp90 as a stimulatory host factor involved in influenza virus RNA synthesis. J Biol Chem 2002; 277: 45306-14.
43. Naito T, Momose F, Kawaguchi A et al. Involvement of Hsp90 in assembly and nuclear import of influenza virus RNA polymerase subunits. J Virol 2007; 81: 1339-49.
44. Geller R, Vignuzzi M, Andino R et al. Evolutionary constraints on chaperone-mediated folding provide an antiviral approach refractory to development of drug resistance. Genes Dev 2007; 21: 195-205.
45. Molla A, Kati W, Carrick R et al. In vitro selection and characterization of influenza A (A/N9) virus variants resistant to a novel neuraminidase inhibitor, A-315675. J Virol 2002; 76: 5380-6.